Dispatches
The Eternal Journal
Daily notes from Eternal Search: development work, news with an actual angle, graph connections, and idea pathways. No ceremonial optimism required.
Tahoe-100M: From Open Preprint to Peer Review in Cell
The Tahoe-100M cancer-cell atlas became a benchmark AI dataset while still an unreviewed preprint; the peer-reviewed paper appeared in Cell roughly 19 months later.
Passenger mutations and survival: AlphaGenome applied to 8,800 tumors
A UT Austin lab applied Google DeepMind's AlphaGenome and AlphaMissense to 8,800 tumors across 33 cancer types: calculated passenger-mutation damage associates with survival independently of total mutation burden, with the effect direction depending on the ...
China's Five-Year Plan Targets Off-the-Shelf Cell Therapy
China's Document No. 210 (September 18, 2026) names off-the-shelf cell therapy a breakthrough target in its 2026-2030 medical industry plan alongside xenotransplantation and organ engineering, with a medical industry revenue target of at least 3.5 trillion ...
More proteasome components, less protein breakdown
Measurements across four stages of replicative senescence show that more proteasome components can coexist with lower activity, so component abundance alone cannot establish improved protein degradation.
Six-phase agentic workflow: 11 vs. 5 correct rare-disease diagnoses on 50 benchmark cases
A preprint extracted a six-phase workflow from seven rare-disease AI systems and ran it against a single GPT-5 prompt on 50 RareBench cases: 11 correct top-ranked diagnoses versus 5, with p=0.0703 falling short of the authors' 0.05 threshold.
UK commission proposes staged approval and post-deployment oversight for medical AI
The UK National Commission published 44 recommendations on 10 September proposing staged MHRA authorization and post-deployment surveillance for medical AI, including recording device versions in patient records.
3D culture and FOSL1 reduce senescence markers in corneal niche cells
Six days in Matrigel reduced senescence markers and boosted division in limbal niche cells; FOSL1 emerged as the transcription factor driving the shift, with mitochondrial function responding to its manipulation in both directions.
GenScript puts HK$1.63 billion into AI drug discovery labs
GenScript is directing 70% of ~HK$2.33 billion in share placement proceeds to automated AI-powered drug discovery infrastructure, with no specific drug candidates named in the announcement.
Cellectis exits two CAR-T programs for liver gene editing
Cellectis stops internal development of two donor-cell CAR-T cancer programs and redirects resources to two preclinical mRNA-based liver gene-editing programs targeting severe lipid disorders, citing a shrinking patient pool and growing competition in later...
archerships proposes human enhancement for coexistence with superintelligent AI
The author behind archerships proposes narrowing the human-AI capability gap through human enhancement and suggests that occupying different environments could support coexistence with future superintelligent AI.
cGAS knockout in killifish: fewer senescence signs, no lifespan gain
Knocking out cGAS in turquoise killifish reduced cellular senescence markers in kidneys and fin cells but did not extend lifespan across 149 fish; in mice, the same deletion shortened life.
ApoD-SUN1 loop impairs young-cell polarity in mice
A bioRxiv preprint shows old fibroblasts secrete ApoD, raising SUN1 in young cells to disrupt their polarity in a self-reinforcing loop that impairs muscle repair in mice.
Hakken narrows 1.5 million hypotheses to three lab tests; two found supporting data
A Hakken preprint reports that two of three AI-selected aging-gene hypotheses showed supporting gene-expression data in cell culture; the three were drawn from 1.5 million scored candidates.
OpenAI cannot rule out that mathematicians' data helped train its models
OpenAI acknowledged it cannot rule out that de-identified data from two mathematicians' use of its products helped improve its models, raising practical questions about data training policies and access documentation for research groups working with AI tools.
Myriad ovine scaffold: 411-patient interim safety data
Interim MASTRR registry data on 411 patients show a 12.2% adverse-event rate with the Myriad ovine extracellular-matrix scaffold, with only one reaction judged probably device-related; enrollment continues toward 800 participants.
Spatial-ATAC-Hi-C maps 2,500 positions across brain and tumor tissue
Spatial-ATAC-Hi-C, published in Nature Methods on September 1, maps 3D chromatin contacts and regulatory DNA accessibility at up to 2,500 positions on one tissue section and was validated in mouse brain before being applied to glioma samples.
SciLaws-Bench separates formula fitting from scientific law discovery
Across 3,616 pairwise comparisons in SciLaws-Bench, a more accurate fit corresponded to greater scientific validity in only 54.9% of cases.
Senescent cells shed mitochondria-laden fragments to survive
A Developmental Cell study shows senescent cells shed membrane-enclosed fragments containing damaged mitochondria; the authors link this shedding to the cell's survival, while the deposited debris stimulates neighboring cells.
Strygin: Repost What You're Ready to Recommend
Alexey Strygin calls on life extension advocates to support peers' strong articles with likes and reposts, provided they have read the piece and are willing to recommend it to their own subscribers.
PIANO separates cell signals from batch effects in a 100M-cell sequencing atlas
PIANO, trained on 100 million cancer-cell profiles, separates cell-type signals from donor, lab, and instrument variation in single-cell RNA sequencing data and reproduces the known gene response to trametinib in preprint validation tests.
Six Sprints Altered 714 Blood Proteins
A study of 19 young men found six 30-second maximal cycling sprints altered 714 blood proteins immediately while 90 minutes of moderate cycling altered seven, with the sprint plasma also producing far larger gene-activity shifts in lab-grown fat cells.
Vitrification in mice: mitochondrial changes that persist into adulthood
A preprint posted 15 August found that mouse offspring from vitrified embryos had impaired left-ventricular mitochondrial respiration in adulthood, with complex III identified as a shared point of vulnerability across IVF and vitrification groups.
ZEUS trial: IL-6 suppressed, cardiovascular events unchanged
The ZEUS trial reduced IL-6 and hsCRP but not cardiovascular events (HR 0.99); Georgakis argues early drug development needs direct plaque measurements, not just blood biomarkers.
VOICE estimates single-cell gene activity from histology images
A University of Michigan preprint describes VOICE, trained on 23.2 million cells across 15 tissue types, which estimates per-cell gene expression from H&E images by combining cell morphology with a reference library of Xenium-measured cells.
Remedium Bio closes $10M Series A to prepare fat-cell protein platform for human trials
Lifespan Vision Ventures announced the initial close of Remedium Bio's $10 million Series A round; the funding will support therapeutic program development and preparations for first-in-human trials, with all published data from cell culture and mouse exper...
TERRA: a 112.6M-cell spatial model turns gene inactivation into testable tissue hypotheses
TERRA, trained on spatial measurements from 112.6 million cells across 20 human tissues, predicts how gene inactivation alters nearby cells; its virtual CTLA4/PDCD1 inactivation yielded a 23-gene signature more strongly expressed in pembrolizumab patients w...
NVIDIA Halos for Robotics: the certification path from demo to factory floor
NVIDIA unveiled Halos for Robotics, a full-stack safety architecture meant to help certify humanoid robots for industrial spaces, with Digit from Agility Robotics as the first partner.
Cambrian Bio ATX-304 Phase 1b: metabolic markers shifted, weight did not
Cambrian Bio presented the first human Phase 1b data for ATX-304, an AMPK activator, at the American Diabetes Association conference: across 23 adults with obesity and prediabetes over 8 weeks, resting energy expenditure rose 8% and liver fat, visceral fat,...
FDA Clears BEAM-304's First Human Trial in PKU
The FDA issued IND clearance for BEAM-304, authorizing Beam Therapeutics to begin a Phase 1/2 trial of liver base editing in phenylketonuria, with no human data yet and the platform model untested in the clinic.
Armstrong's 'Gattaca Stack' vs. 2.5 IQ Points
Brian Armstrong called his IVF-to-heritable-editing vision a 'Gattaca stack'; a 2019 Cell estimate puts actual IQ gain from five-embryo selection at about 2.5 points; Eternal Search tracks where his biotech and longevity capital goes.
Nature tests MIRA and AMIE as clinical workflow agents
Nature published two papers testing medical AI agents in clinical work: MIRA achieved 87.8% diagnostic accuracy versus 78.1% for four board-certified physicians on 311 ICU cases from MIMIC-IV, and AMIE matched or exceeded physicians on outpatient management...
ISM8969 first-in-human: can an NLRP3 inhibitor reach the brain?
Insilico and Hygtia dosed the first participant with ISM8969 on June 17; Phase I in Australia will test safety and whether this NLRP3 inhibitor actually reaches the brain.
ENPIRE: eight agents, real robots, and who pays for each attempt
NVIDIA's ENPIRE scaled from one Codex agent to eight on physical robot tasks, cutting pin-insertion time from 1.5 hours to 40 minutes, but token costs grew superlinearly and two of three agents failed Push-T on real hardware.
HHMI commits $500M to AI-guided biology, admits the tools aren't there yet
HHMI's Janelia launches a decade-long program to explain how a vertebrate brain generates behavior, using the transparent fish Danionella and AI-in-the-Loop experiments, within the $500 million AI@HHMI portfolio, openly stating that scientists do not yet kn...
Insilico's 30-candidate pipeline and one patient dataset
Zhavoronkov's 30-candidate count checks out against Insilico's pipeline page and ClinicalTrials.gov, but the most detailed patient data covers 71 people over 12 weeks in a safety-primary trial of rentosertib; Zhavoronkov holds rank 4 among Eternal Search lo...
A chromosome from a frozen rat produced RNA again in a living mouse
Wakayama's group derived 17 ES cell lines from a rat frozen over a year; two retained rat chromosome 9, which showed 64 expression peaks matching rat heart tissue in chimeric mice, demonstrating that frozen genetic material can produce RNA again in a living...
Synthetic genome restarts: £10M for 2% of DNA
The 2016 synthetic genome project stayed a collection of pilots and meetings; British SynHG now has £10 million from Wellcome for chromosome synthesis tools, and Pinglay proposes the minimal human genome as the new goal.
Alcor upgrades its dewars and skips the specs
Alcor unveiled a new super-dewar on LinkedIn without a single published specification, even though its separate nitrogen-reserve expansion came with concrete numbers; the last dewar performance data is from 2008.
64 pull requests, 19 projects, and the maintainer problem
In its first week, OpenAI's Patch the Planet produced 64 pull requests across 19 open-source projects, but the harder problem is getting patches through the full path: accepted by maintainers, tested, released, and installed by users.
Medical AI reads the test, not the image
A Nature Medicine study by Eric Topol and Microsoft Research found GPT-5 scores 41.32% on image-dependent NEJM diagnostic tasks even with the image removed (random baseline: 20%), because the model exploits question wording and answer structure rather than ...
Young ovary, aging brain: the hypothalamic bottleneck in reproductive aging
1980s transplantation experiments, reinforced by 2025 OSKM data, show that an aging hypothalamic-pituitary axis can block cycle restart even with a functioning young ovary present, complicating approaches that target only the ovary.
Jensen: the longevity field turns aging mechanisms into startups faster than it finds new ones
Martin Borch Jensen argues the longevity field is turning existing aging mechanisms into companies and clinical programs faster than discovering new ones; his nonprofit Norn Group has distributed over $34M across 145 early-stage projects through Impetus Gra...
Drug-stabilizing proteins from NISE, and what they mean for senolytics
Harvard and Dana-Farber's NISE loop designed proteins that kept over 99% of an anticancer drug in active form for 50 hours at physiological pH; senolytics are among the future applications where this molecular control matters.
Levin team shows nuclear membrane voltage depends on a cell's ionic history
A June 24 bioRxiv preprint from Michael Levin's team at Tufts, Harvard Wyss Institute, and MIT measured voltage on the inner nuclear membrane of a living cell, showing the response depends on ionic trajectory and is linked to chromatin state, adding a bioph...
Aleph maps brain vessels through intact skull: the BCI gap
Aleph published a 3D vascular map of the living brain captured through an intact skull with ultrasound and microbubble contrast, but the promised brain-computer interface requires extracting a far weaker signal without any contrast agent, a step Aleph still...
Johnson vs Klein: the argument biomarkers can't settle
Johnson's June 21 rebuttal of Klein's dystopia framing slides from biology into moral philosophy; the concrete question, what Johnson has actually contributed to longevity science, is one the debate does not reach.
Templeton: $60M+ for Intelligence Venture, Life Sciences deadline July 15
John Templeton Foundation is accepting Life Sciences applications through July 15, 2026; the cycle is tied to Intelligence Venture ($60M+ over three years across six funding areas), with measurability required, clinical research excluded, and Levin/Pio-Lope...
LifeSciBench: best AI passes 36% of real biology tasks
LifeSciBench tests AI on 750 real biology tasks — top score is 36.1%, 171 tasks stumped every model, and performance drops further on anything beyond plain text.
BoltzProt-1 shifts the drug-discovery bottleneck from computation to the wet lab
BoltzProt-1 raises confirmed binder rates from 3.3% to 8% on difficult targets; with both models available via API, the bottleneck moves toward lab validation.
Right to Try 2.0 meets gene therapy reality
A new U.S. bill exposes the bad fit between mass-market drug rules and experimental therapies built for one patient.
NeuroPEEM Is Infrastructure, Not a Digital Brain
NeuroPEEM’s 300x faster-cheaper claim matters because it targets the imaging bottleneck in connectomics, with the University of Chicago sitting behind the infrastructure bet.
FDA draft trims repetition, not regulation
The FDA’s draft genome-editing guidance may let platform companies reuse some evidence, but it does not create an anti-aging pathway or remove new off-target checks.
Stem Cells, Now Measured
China’s 2,000-person amimestrocel trial matters because it tests function and safety in older adults, not the old stem-cell rejuvenation sales pitch.
84% in mice is not a human breakthrough
Immorta Bio's mouse result is a real preclinical signal for senolytics, not proof that a two-part anti-aging therapy now works in humans.